Hyaline membrane disease is a breathing disorder of newborns caused by a shortage of surfactant, the slippery coating that keeps the lungs’ tiny air sacs from collapsing. It overwhelmingly strikes premature babies, particularly those born before 34 weeks of gestation, and it remains one of the leading reasons a newborn ends up in intensive care. The condition is now more commonly called neonatal respiratory distress syndrome (RDS), but the older name persists because it describes the glassy membranes pathologists see lining the air sacs of affected lungs. Although survival rates have improved dramatically since the mid-twentieth century, the disease still carries serious risks, especially in parts of the world where surfactant therapy and advanced neonatal care are hard to come by.
What Surfactant Does and Why Premature Lungs Lack It
The lungs contain millions of air sacs called alveoli. Each time you exhale, those sacs shrink. Without something to lower the surface tension at their inner walls, they would stick shut like a wet plastic bag. Surfactant is the substance that prevents that collapse. It is a mixture of fats and proteins produced by specialized cells in the alveolar lining, and it allows the sacs to spring open again with each new breath.1Bentham Science Publishers. Persistent Respiratory Distress in the Term Neonate: Genetic Surfactant Deficiency Diseases
Among the proteins in the surfactant mixture, two in particular, SP-B and SP-C, are critical for getting the lipid components to spread rapidly across the air-liquid boundary. Without them, surfactant cannot do its job even if the lipid ingredients are present.2PubMed. Kinetics of phospholipid insertion into monolayers containing the lung surfactant proteins SP-B or SP-C
Fetal lungs do not begin producing meaningful amounts of surfactant until roughly the third trimester, and production ramps up significantly between about 32 and 36 weeks of gestation. A baby born well before that window simply has not had enough time to build an adequate supply. The earlier the birth, the greater the deficit, which is why babies born before 34 weeks face substantially higher odds of developing the disease.3PubMed Central. The burden of hyaline membrane disease, mortality and its determinant factors among preterm neonates admitted at Debre Tabor General Hospital, North Central Ethiopia
Who Is at Risk Beyond Prematurity
Gestational age is the single strongest predictor, but it is not the only one. Maternal diabetes independently raises the odds. A landmark study comparing more than 800 infants of diabetic mothers with over 10,000 infants of non-diabetic mothers found that the syndrome appeared in about 23 percent of the diabetic group versus roughly 1 percent of the non-diabetic group. Even after controlling for factors like gestational age and delivery method, infants of diabetic mothers were still about five and a half times more likely to develop the disease.4PubMed. Association between maternal diabetes and the respiratory-distress syndrome in the newborn The mechanism is thought to involve the way high maternal blood sugar and elevated fetal insulin interfere with the biochemical signals that trigger surfactant production.
Cesarean delivery before labor begins is another recognized risk factor. During vaginal birth, hormonal surges help squeeze fluid out of the fetal lungs and stimulate surfactant release. A scheduled cesarean, especially one performed before 39 weeks, bypasses those signals. Male sex is a risk factor as well; boys are somewhat more prone to surfactant deficiency than girls at the same gestational age, likely because androgens slow lung maturation while estrogens promote it. Other contributors include being a twin, perinatal asphyxia, and hypothermia at birth.
What the Disease Looks Like in the First Hours
Symptoms typically appear within minutes to a few hours after birth. The baby breathes fast, often more than 60 breaths per minute, and each breath looks effortful. The muscles between the ribs pull inward visibly, and the nostrils flare. A characteristic expiratory grunting sound occurs as the infant instinctively tries to keep the air sacs open by partially closing the vocal cords. The skin may turn bluish, reflecting low oxygen levels. Without intervention, the breathing difficulty tends to worsen over the first day or two as the available surfactant is used up and the lungs stiffen further.
A chest X-ray is the standard way to confirm the diagnosis. The classic image shows a hazy, ground-glass pattern across both lung fields, with visible air-filled airways standing out against the opaque lung tissue. Doctors sometimes describe the appearance as “air bronchograms.” In severe cases, the lungs look almost completely white on the X-ray because so many air sacs have collapsed.
The Gastric Shake Test and Bedside Diagnosis
In well-equipped hospitals, blood gas measurements and imaging confirm the diagnosis quickly. But in resource-limited settings, a remarkably simple bedside test can help. The gastric shake test uses a small sample of stomach contents aspirated from the newborn shortly after birth. Because a fetus swallows amniotic fluid in the womb, the stomach contents reflect the surfactant level in the lungs. The sample is mixed with ethanol and shaken; if stable bubbles form at the surface, surfactant is present. One study found that the test had 100 percent sensitivity and 92 percent specificity for detecting surfactant deficiency, meaning it caught every baby who went on to develop respiratory distress and gave a false alarm in only a small fraction of healthy infants.5PubMed Central. Diagnostic value of gastric shake test for hyaline membrane disease in preterm infant It is not a replacement for modern diagnostics, but in a rural clinic without immediate access to imaging, it can guide the decision to transfer a baby to a higher-level facility.
Prevention with Antenatal Steroids
The single most effective way to prevent or reduce the severity of hyaline membrane disease is to give the mother corticosteroids before a preterm delivery. A course of injections, usually betamethasone or dexamethasone, crosses the placenta and accelerates surfactant production in the fetal lungs. A large Cochrane review pooling data from dozens of randomized trials found that antenatal corticosteroids reduced the risk of RDS by about a third and cut the risk of moderate-to-severe disease by roughly 40 percent. They also reduced the risk of neonatal death by about 31 percent.6PubMed Central. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth Updated reviews have continued to support these findings, reinforcing the recommendation that a single course of antenatal corticosteroids should be standard care for women at risk of preterm delivery.7Cochrane Database of Systematic Reviews. Antenatal corticosteroids to accelerate fetal lung maturation for women at risk of preterm birth
The catch is timing. The steroids need at least 24 to 48 hours to work before delivery. When labor is already progressing rapidly, there may not be enough time for the full effect. Obstetricians weigh the benefits against the small risks of steroid exposure, but in practice the risk-benefit calculation overwhelmingly favors treatment for pregnancies at high risk of delivery before 34 weeks.
Surfactant Replacement Therapy
Once a baby is born and shows signs of the disease, the frontline treatment is direct surfactant replacement. A liquid surfactant preparation, derived from animal lungs or produced synthetically, is delivered into the baby’s airway, usually through a thin tube. This was the breakthrough therapy of the late twentieth century, and its impact has been enormous. A systematic review combining data from multiple studies found that surfactant replacement reduced the risk of death by about a third and also significantly lowered the risk of air leaks, a dangerous complication in which air escapes from the lungs into the chest cavity.8Journal of Perinatology. Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low- and middle-income countries: a systematic review
The way surfactant is delivered has evolved considerably. Traditional methods required placing a breathing tube (endotracheal intubation) and mechanically ventilating the baby, which itself carries risks of lung injury. Newer approaches pair non-invasive breathing support, such as continuous positive airway pressure (CPAP), with minimally invasive surfactant delivery through a thin catheter threaded into the airway while the baby continues to breathe on its own. Evidence suggests this pairing allows the surfactant to spread more naturally through the lungs and reduces the time a baby spends on a ventilator.9PubMed Central. Non-invasive respiratory support paired with minimally invasive surfactant therapy in preterm infants
The Cost Barrier in Low-Resource Settings
Surfactant is expensive. A single dose can cost hundreds of dollars, and many babies need more than one. In high-income countries this cost is absorbed by hospital budgets or insurance, but in lower-income settings it often falls on families. One survey from a low-resource hospital found that families had to pay out of pocket for the surfactant and other supplies; nearly a quarter of the treated babies still died, and financial barriers were identified as a major constraint to wider use of the therapy.10Taylor & Francis Online (J Matern Fetal Neonatal Med). The minimal invasive surfactant therapy: experience from a low resource setting This gap helps explain why hyaline membrane disease remains a significant cause of newborn death in sub-Saharan Africa and South Asia even though effective treatments exist. The challenge is not purely pharmacological; it is logistical and economic.
Bronchopulmonary Dysplasia and Other Long-Term Complications
Surviving hyaline membrane disease does not always mean the lungs recover fully. The most common long-term complication is bronchopulmonary dysplasia (BPD), a chronic lung condition that develops after prolonged exposure to oxygen therapy and mechanical ventilation. BPD is now understood as the result of disrupted lung development, where the normal process of building new alveoli is derailed by both the original injury and the treatments used to keep the baby alive.11PubMed Central. Bronchopulmonary dysplasia Older research found a strong statistical link between the most severe BPD lesions, including airway damage and scarring, and the use of high ventilation pressures during mechanical breathing support.12PubMed Central. Pathogenesis of bronchopulmonary dysplasia following hyaline membrane disease
This is one of the reasons neonatologists have shifted toward gentler ventilation strategies over the decades. The move from aggressive mechanical ventilation to CPAP and minimally invasive surfactant delivery is driven partly by the desire to reduce BPD rates. Even so, BPD remains the most frequent complication of extreme preterm birth, and many survivors carry some degree of lung vulnerability into childhood and beyond.
Beyond the lungs, babies who survive severe RDS also face higher rates of neurodevelopmental problems. Research has found that markers of oxidative stress measured in the newborn period, when the body’s production of damaging molecules outstrips its defenses, correlate with abnormal developmental outcomes at two years of age.13IOS Press / PubMed Central. Prognostic Utility of Pro-Oxidant-Antioxidant Balance in Preterm Neonates with Respiratory Distress Syndrome The severity of the initial lung disease appears to compound these risks, meaning that prevention and early, effective treatment matter not just for immediate survival but for the child’s long-term brain development.
When Full-Term Babies Get It
Although hyaline membrane disease is overwhelmingly a disease of prematurity, it occasionally strikes babies born at full term. In these cases, the cause is usually not immaturity but a genetic defect in one of the genes responsible for making surfactant or transporting its components. Mutations in genes called SFTPB, SFTPC, NKX2-1, and ABCA3 can all disrupt surfactant production or packaging. A baby born at 40 weeks with one of these mutations can present with the same severe respiratory distress as a 28-weeker.14PubMed Central. The most frequent ABCA3 nonsense mutation -p.Tyr1515* (Y1515X) causing lethal neonatal respiratory failure in a term neonate
These genetic forms are rare but often devastating. Some SFTPB mutations are lethal without a lung transplant. ABCA3 mutations vary in severity; some cause fatal disease in the newborn period, while others lead to a chronic interstitial lung disease that surfaces later in infancy or childhood. The existence of these genetic conditions is a reminder that surfactant deficiency is not solely a problem of being born too early. It is a problem of not having enough functional surfactant, whatever the reason.
The Historical Turning Point
For much of the twentieth century, hyaline membrane disease was essentially untreatable. Doctors could provide oxygen and supportive care, but without surfactant the disease killed tens of thousands of newborns every year. The condition drew enormous public attention in 1963 when Patrick Bouvier Kennedy, the two-day-old son of President John F. Kennedy, died of hyaline membrane disease. His death, along with the roughly half a million other HMD deaths that year worldwide, galvanized research funding into surfactant biology.15PubMed. Historical perspective on surfactant therapy: Transforming hyaline membrane disease to respiratory distress syndrome
Over the following decades, researchers worked out the composition of surfactant, developed methods to extract it from animal lungs, and ran the clinical trials that proved replacement therapy saved lives. By the early 1990s, surfactant therapy had become standard of care in neonatal intensive care units across wealthy nations. The shift from the old name “hyaline membrane disease” to the broader term “respiratory distress syndrome” reflects that change in understanding: the disease is defined by what is missing (surfactant), not just by what pathologists see under the microscope.
Aerosolized Surfactant and the Search for Better Delivery
Even minimally invasive catheter techniques require a degree of clinical skill and equipment that may not be available everywhere. One line of research aims to deliver surfactant as an aerosol, sprayed into the baby’s airway through a CPAP interface so that no catheter needs to enter the trachea at all. The engineering challenge is formidable: a premature infant’s airways are tiny, breathing rates are very fast, and the volume of each breath is small, so most of the aerosol tends to deposit in the equipment or the upper airway rather than reaching the deep lung. Researchers have been developing specialized nasal prong interfaces and computational models to optimize airflow and particle deposition so that a meaningful dose actually arrives where it is needed.16PubMed. Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants If this technology matures, it could simplify treatment enough to make surfactant therapy practical in settings that currently cannot offer it.
Surfactant Across the Animal Kingdom
Humans are far from the only species that rely on pulmonary surfactant. Research into comparative biology has revealed that the surfactant system is remarkably conserved across air-breathing vertebrates, from frogs and lizards to birds and mammals. Temperature appears to be the main environmental factor shaping surfactant composition across species: animals that breathe in colder environments tend to have surfactant with a different lipid profile than those in warmer climates. One of the most ancient functions of surfactant may not even be keeping air sacs open; comparative studies suggest that acting as an anti-adhesive, preventing the moist inner surfaces of the lung from sticking together, is a primitive and universal role of this substance.17PubMed. The comparative biology of pulmonary surfactant: past, present and future The fact that evolution has preserved this system for hundreds of millions of years underscores just how essential it is. A premature human baby struggling to breathe is, in a sense, facing the consequences of being born before its body has finished building one of the oldest protective systems in vertebrate biology.